Andrew Berens

Stock Analyst at Leerink Partners

(1.08)
# 1932
Out of 5,333 analysts
221
Total ratings
48.54%
Success rate
-2.37%
Average return
40 Stocks
Name Action PT Current % Upside Ratings Updated
CMPX Compass Therapeutics
Upgrades: Outperform
4 6
1.79 235.2% 3 Apr 2, 2025
ELEV Elevation Oncology
Downgrades: Market Perform
9 1
0.36 177.78% 5 Mar 21, 2025
OKUR OnKure Therapeutics
Initiates Coverage On: Outperform
33
2 1550% 1 Dec 5, 2024
ZYME Zymeworks
Upgrades: Outperform
10 25
11.29 121.43% 10 Nov 7, 2024
GILD Gilead Sciences
Upgrades: Outperform
74 96
98.35 -2.39% 1 Oct 21, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
60 56
28.07 99.5% 11 Sep 27, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
5 3
n/a n/a 5 Aug 16, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
29
10.5 176.19% 1 Jul 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Market Perform
50 97
98.89 -1.91% 24 May 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
69 110
71.54 53.76% 1 Apr 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
78
59.73 30.59% 12 Dec 13, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
78 58
n/a n/a 7 Nov 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
13 10
n/a n/a 2 May 16, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
35 48
42.8 12.15% 5 Apr 17, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
30
n/a n/a 11 Feb 8, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
162 141
n/a n/a 19 Feb 6, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
236 300
n/a n/a 11 Jan 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
18 20
4.98 301.61% 4 Jan 5, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
37 28
9.65 190.16% 3 Dec 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
74 70
6.8 929.41% 5 Nov 23, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
78 79
67.3 17.38% 12 Nov 14, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
42 27
1.26 2042.86% 7 Nov 10, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 4 Oct 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
40 30
1.45 1968.97% 4 Aug 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
69
n/a n/a 4 Aug 9, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
101 76
n/a n/a 6 Jun 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
25 23
n/a n/a 5 May 27, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
36 25
7.78 221.34% 3 May 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
40
5.81 588.47% 1 Nov 23, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
28
n/a n/a 1 Nov 1, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
67
1.54 4250.65% 1 Oct 14, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
20
4.21 375.06% 1 Oct 14, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
25
1.1 2172.73% 1 Sep 20, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
12 16
n/a n/a 5 May 7, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underperform
4 3
n/a n/a 6 Nov 6, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reinstates: Overweight
2000
n/a n/a 2 Sep 7, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
156 146
n/a n/a 3 Mar 1, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
102 18
n/a n/a 2 Sep 22, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Underweight
75 50
n/a n/a 5 Sep 22, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Equal-Weight
16 8
7.46 7.24% 7 Jul 14, 2017